... Gendicine was intratumorally injected once a week for a total of 6 weeks and radiotherapy was given 3 days after the first injection of Gendicine. Then the patients were followed up every 2 months. In combination group, 5/15 patients ...
... Gendicine as a recombinant adenovirus particle, besides the functions of p53 gene, which has been observed in clinical practice. 10.4. Safety. of. Gendicine. in. Clinics. Comprehensive, multiyear, multicenter clinical studies have been ...
... Gendicine in combination with radiation therapy 29% of the patients experienced partial regression. Among all the patients, about 75% suffered from advanced nasopharyngeal carcinoma, which is a sub-indication of head-and-neck cancer ...
... (Gendicine®, Glybera® and Oncorine®) are delivered by viral vectors. Gendicine, which is delivered in an adenovirus vector, is produced as a viral particle. The Gendicine adenovirus consists of an E1 gene deleted adenoviral vector, with ...
... Gendicine Gendicine is a recombinant adenovirus engineered to express the tumorsuppressing gene p53 for patients with head and neck squamous cell carcinoma. It was approved by the Chinese Food and Drug Administration in 2003 [127]. When ...
... Gendicine due to the large proportion of skin cancer patients in China and the significance of Gendicine in saving many lives (People's Daily, 2004). Nevertheless, given the controversial results from Phase I and II and the small number ...
... Gendicine. It was founded in 1998 in Shenzhen half a year before a prototype of Gendicine; a normal human p53 gene engineered into an adenoviral vector was cleared for clinical trials (the p53 gene plays a key role in at least half of ...
... Gendicine Gendicine is the tradename given to the first gene - therapy - based medicine approved anywhere in the world . It gained approval for use in the treatment of head and neck squamous cell car- cinoma from China's State Food and ...
... Gendicine and radiation to radiation alone in HNSCC patients . The regimen for the combination therapy was that the patient would receive one dose of 1x1012 vp Gendicine each week followed by radiotherapy and repeat this therapy cycle ...
... Gendicine (a recombinant human p53 adenovirus), which was approved by the China Food and Drug Administration (CFDA) in 2003 as a first-in-class gene therapy treatment to treat head and neck cancers. It is a biological therapy that can ...